𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Animal models of rheumatoid arthritis

✍ Scribed by Asquith, Darren L. (author);Miller, Ashley M. (author);McInnes, Iain B. (author);Liew, Foo Y. (author)

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
104 KB
Volume
39
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Animal models of rheumatoid arthritis
Animal models of rheumatoid arthritis
✍ Asquith, Darren L. (author);Miller, Ashley M. (author);McInnes, Iain B. (author) πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 104 KB

## Abstract Animal models have been used extensively in studies of rheumatoid arthritis pathogenesis. Despite the inherent limitations of all animal models, several rodent models have significantly progressed our understanding of the fundamental mechanisms underpinning rheumatoid arthritis and cont

Blockade of the interleukin-21/interleuk
Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis
✍ Deborah A. Young; Martin Hegen; Hak Ling Margery Ma; Matthew J. Whitters; Leo M. πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 595 KB

## Abstract ## Objective Interleukin‐21 (IL‐21) is a T cell–derived cytokine that modulates T cell, B cell, and natural killer cell responses. In this study, the effects of blocking IL‐21 were examined in 2 rodent models of rheumatoid arthritis (RA) to determine whether IL‐21 contributes to their

Combination benefit of treatment with th
Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis
✍ Alison M. Bendele; Elizabeth S. Chlipala; Jon Scherrer; Janet Frazier; Gina Senn πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 695 KB

Objective. To determine the potential for additive or synergistic effects of combination therapy with the recombinant anticytokine agents interleukin-1 receptor antagonist (IL-1Ra) and PEGylated soluble tumor necrosis factor receptor type I (PEG sTNFRI) in established type II collagen-induced arthri